Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells

Nanomedicine

Volumn 9, Issue 14, 2014, Pages 2123-2141

  Reynolds, Lacy ^a   Mulik, Rohit S ^a   Wen, Xiaodong ^a   Dilip, Archana ^b   Corbin, Ian R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Docosahexaenoic acid; Liver cancer; Low density lipoprotein; Low density lipoprotein receptor; Nanoparticle; Omega 3 fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; DRUG CARRIER; HUMAN SERUM ALBUMIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN NANOPARTICLE; NANOPARTICLE; OLEIC ACID; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG STABILITY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION; PROTEIN SECONDARY STRUCTURE; THERAPY EFFECT; ANIMAL; CELL DEATH; COCULTURE; DRUG EFFECTS; EXPERIMENTAL LIVER NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DOCOSAHEXAENOIC ACIDS; LIPOPROTEINS, LDL; LIVER NEOPLASMS, EXPERIMENTAL; MICE;

EID: 84911480178     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/NNM.13.187     Document Type: Article

References (80)

1. Caygill CP, Charlett A, Hill MJ. Fat, fish, fish oil and cancer. Br. J. Cancer 74(1), 159-164 (1996).
2. Sasazuki S, Inoue M, Iwasaki M et al. Intake of n-3 and n-6 polyunsaturated fatty acids and development of colorectal cancer by subsite: Japan Public Health Center-based prospective study. Int. J. Cancer 129(7), 1718-1729 (2011).
3. Sawada N, Inoue M, Iwasaki M et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 142(7), 1468-1475 (2012).
4. Berquin IM, Min Y, Wu R et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J. Clin. Invest. 117(7), 1866-1875 (2007).
5. Iwamoto S, Senzaki H, Kiyozuka Y et al. Effects of fatty acids on liver metastasis of ACL-15 rat colon cancer cells. Nutr. Cancer 31(2), 143-150 (1998).
6. Braden LM, Carroll KK. Dietary polyunsaturated fat in relation to mammary carcinogenesis in rats. Lipids 21(4), 285-288 (1986).
7. Kang KS, Wang P, Yamabe N, Fukui M, Jay T, Zhu BT. Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase 8 activation. PLoS ONE 5(4), e10296 (2010).
8. Lim K, Han C, Dai Y, Shen M, Wu T. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol. Cancer Ther. 8(11), 3046-3055 (2009).
9. Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P, Johnsen JI. Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int. J. Cancer 118(10), 2584-2593 (2006).
10. Conquer JA, Holub BJ. Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. J. Lipid Res. 39(2), 286-292 (1998).
11. Gleissman H, Segerstrom L, Hamberg M et al. Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo . Int. J. Cancer 128(7), 1703-1711 (2011).
12. Noguchi M, Minami M, Yagasaki R et al. Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. Br. J. Cancer 75(3), 348-353 (1997).
13. Swamy MV, Citineni B, Patlolla JM, Mohammed A, Zhang Y, Rao CV. Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr. Cancer 60(Suppl. 1), 81-89 (2008).
14. Gupta A, Reilly CS. Fat embolism. Contin. Educ. Anaesth. Crit. Care Pain. 7(5), 148-151 (2007).
15. Namani T, Ishikawa T, Morigaki K, Walde P. Vesicles from docosahexaenoic acid. Colloids Surf. B Biointerfaces 54(1), 118-123 (2007).
16. Kanno S, Kurauchi K, Tomizawa A, Yomogida S, Ishikawa M. Albumin modulates docosahexaenoic acid-induced cytotoxicity in human hepatocellular carcinoma cell lines. Toxicol. Lett. 200(3), 154-161 (2011).
17. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 582(13), 1783-1787 (2008).
18. Gura KM, Duggan CP, Collier SB et al . Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 118(1), e197-e201 (2006).
19. Lutz O, Meraihi Z, Mura JL, Frey A, Riess GH, Bach AC. Fat emulsion particle size: influence on the clearance rate and the tissue lipolytic activity. Am. J. Clin. Nutr. 50(6), 1370-1381 (1989).
20. Oliveira FL, Rumsey SC, Schlotzer E, Hansen I, Carpentier YA, Deckelbaum RJ. Triglyceride hydrolysis of soy oil vs fish oil emulsions. J. Parenter. Enteral Nutr. 21(4), 224-229 (1997).
21. Marotta DE, Cao WG, Wileyto EP et al. Evaluation of bacteriochlorophyll-reconstituted low-density lipoprotein nanoparticles for photodynamic therapy efficacy in vivo. Nanomedicine (Lond.) 6(3), 475-487 (2011).
22. Shahzad MM, Mangala LS, Han HD et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4), 309-319 (2011).
23. Zhou P, Hatziieremia S, Elliott MA et al. Uptake of synthetic low density lipoprotein by leukemic stem cells - a potential stem cell targeted drug delivery strategy. J. Control. Release 148(3), 380-387 (2010).
24. Corbin IR, Ng KK, Ding L, Jurisicova A, Zheng G. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (Lond.) 8(6), 875-890 (2013).
25. Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 44(10), 1105-1113 (2011).
26. Gotto AM Jr, Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. Methods Enzymol. 128, 3-41 (1986).
27. Favre G. [Targeting of tumor cells by low density lipoproteins: principle and use of ellipticin derivatives]. C R Seances Soc. Biol. Fil. 186(1-2), 73-87 (1992).
28. Gal D, Ohashi M, MacDonald PC, Buchsbaum HJ, Simpson ER. Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am. J. Obstet. Gynecol. 139(8), 877-885 (1981).
29. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52(6), 1099-1114 (1978).
30. Lund-Katz S, Laplaud PM, Phillips MC, Chapman MJ. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry 37(37), 12867-12874 (1998).
31. Krieger M, McPhaul MJ, Goldstein JL, Brown MS. Replacement of neutral lipids of low density lipoprotein with esters of long chain unsaturated fatty acids. J. Biol. Chem. 254(10), 3845-3853 (1979).
32. Pitas RE, Innerarity TL, Weinstein JN, Mahley RW. Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy. Arteriosclerosis 1(3), 177-185 (1981).
33. Erdahl WL, Krebsbach RJ, Pfeiffer DR. A comparison of phospholipid degradation by oxidation and hydrolysis during the mitochondrial permeability transition. Arch. Biochem. Biophys. 285(2), 252-260 (1991).
34. Counsell RE, Pohland RC. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J. Med. Chem. 25(10), 1115-1120 (1982).
35. Krieger M, Brown MS, Faust JR, Goldstein JL. Replacement of endogenous cholesteryl esters of low density lipoprotein with exogenous cholesteryl linoleate. Reconstitution of a biologically active lipoprotein particle. J. Biol. Chem. 253(12), 4093-4101 (1978).
36. Firestone RA. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug. Chem. 5(2), 105-113 (1994).
37. Kader A, Davis PJ, Kara M, Liu H. Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J. Control. Release 55(2-3), 231-243 (1998).
38. Masquelier M, Vitols S, Palsson M, Mars U, Larsson BS, Peterson CO. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood. J. Drug Target. 8(3), 155-164 (2000).
39. Masquelier M, Tirzitis G, Peterson CO et al. Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. Eur. J. Med. Chem. 35(4), 429-438 (2000).
40. Lestavel-Delattre S, Martin-Nizard F, Clavey V et al. Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res. 52(13), 3629-3635 (1992).
41. Hammel M, Laggner P, Prassl R. Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system. Chem. Phys. Lipids 123(2), 193-207 (2003).
42. Edwards IJ, Berquin IM, Sun H et al. Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin. Clin. Cancer Res. 10(24), 8275-8283 (2004).
43. Hevonoja T, Pentikainen MO, Hyvonen MT, Kovanen PT, Ala-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim. Biophys. Acta 1488(3), 189-210 (2000).
44. Wang L, Walsh MT, Small DM. Apolipoprotein B is conformationally flexible but anchored at a triolein/water interface: a possible model for lipoprotein surfaces. Proc. Natl Acad. Sci. USA 103(18), 6871-6876 (2006).
45. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42(9), 1346-1367 (2001).
46. Aggerbeck LP, Kezdy FJ, Scanu AM. Enzymatic probes of lipoprotein structure. Hydrolysis of human serum low density lipoprotein-2 by phospholipase A2. J. Biol. Chem. 251(12), 3823-3830 (1976).
47. Jayaraman S, Gantz DL, Gursky O. Effects of oxidation on the structure and stability of human low-density lipoprotein. Biochemistry 46(19), 5790-5797 (2007).
48. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. Physico-chemical stability of colloidal lipid particles. Biomaterials 24(23), 4283-4300 (2003).
49. Schuh J, Fairclough GF Jr, Haschemeyer RH. Oxygen-mediated heterogeneity of apo-low-density lipoprotein. Proc. Natl Acad. Sci. USA 75(7), 3173-3177 (1978).
50. Singh S, Lee DM. Conformational studies of lipoprotein B and apolipoprotein B: effects of disulfide reducing agents, sulfhydryl blocking agent, denaturing agents, pH and storage. Biochim. Biophys. Acta 876(3), 460-468 (1986).
51. Duh P-D, Yen W, Yen G-C. Oxidative stability of polyunsaturated fatty acids and soybean oil in an aqueous solution with emulsifiers. J. Amer. Oil Chem. Soc. 76(2), 201-204 (1999).
52. Miyashita K, Nara E, Ota T. Oxidative stability of polyunsaturated fatty acids in an aqueous solution. Biosci. Biotechnol. Biochem. 57(10), 1638-1640 (1993).
53. Khan MA, Shahidi F. Tocopherols and phospholipids enhance the oxidative stability of borage and evening primrose triacylglycerols. J. Food Lipids 7(3), 143-150 (2000).
54. Zimet P, Livney YD. Beta-lactoglobulin and its nanocomplexes with pectin as vehicles for @w-3 polyunsaturated fatty acids. Food Hydrocol. 23(4), 7-7 (2009).
55. Moller M, Botti H, Batthyany C, Rubbo H, Radi R, Denicola A. Direct measurement of nitric oxide and oxygen partitioning into liposomes and low density lipoprotein. J. Biol. Chem. 280(10), 8850-8854 (2005).
56. de Ruiz GJ, Mertxe de R, del Cerro A, de Fernandez LE, Amiano P, Dorronsoro M. Habitual fish intake is associated with decreased LDL susceptibility to ex vivo oxidation. Lipids 37(4), 333-341 (2002).
57. Calzada C, Colas R, Guillot N et al. Subgram daily supplementation with docosahexaenoic acid protects low-density lipoproteins from oxidation in healthy men. Atherosclerosis 208(2), 467-472 (2010).
58. Schuster B, Prassl R, Nigon F, Chapman MJ, Laggner P. Core lipid structure is a major determinant of the oxidative resistance of low density lipoprotein. Proc. Natl Acad. Sci. USA 92(7), 2509-2513 (1995).
59. Shangguan D, Meng L, Cao ZC et al. Identification of liver cancer-specific aptamers using whole live cells. Anal. Chem. 80(3), 721-728 (2008).
60. Martin-Orozco E, Chicano A, Ruiz-Alcaraz AJ et al. Synthetic oligodeoxynucleotides induce MAP kinases activation in murine TIB-73 hepatocytes. Histol. Histopathol. 25(7), 831-840 (2010).
61. Ogunwobi OO, Liu C. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin. Exp. Metastasis 28(8), 721-731 (2011).
62. Nakagawa T, Ueyama Y, Nozaki S et al. Marked hypocholesterolemia in a case with adrenal adenoma - enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells. J. Clin. Endocrinol. Metab. 80(1), 92-96 (1995).
63. Peterson C, Vitols S, Rudling M, Blomgren H, Edsmyr F, Skoog L. Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med. Oncol. Tumor Pharmacother. 2(3), 143-147 (1985).
64. Brissette L, Falstrault L. Analysis of the binding and association of human intermediate density lipoproteins to HepG2 cells. Biochim. Biophys. Acta 1165(1), 84-92 (1992).
65. Ye ZJ, Go GW, Singh R, Liu W, Keramati AR, Mani A. LRP6 protein regulates low density lipoprotein (LDL) receptor-mediated LDL uptake. J. Biol. Chem. 287(2), 1335-1344 (2012).
66. Dippenaar N, Booyens J, Fabbri D, Engelbrecht P, Katzeff IE. The reversibility of cancer: evidence that malignancy in human hepatoma cells is gamma-linolenic acid deficiency-dependent. S. Afr. Med. J. 62(19), 683-685 (1982).
67. Leary WP, Robinson KM, Booyens J, Dippenaar N. Some effects of gamma-linolenic acid on cultured human oesophageal carcinoma cells. S. Afr. Med. J. 62(19), 681-683 (1982).
68. Pande SV, Mead JF. Inhibition of enzyme activities by free fatty acids. J. Biol. Chem. 243(23), 6180-6185 (1968).
69. Shaw W. Possible role of lysolecithins and nonesterified fatty acids in the pathogenesis of Reye's syndrome, sudden infant death syndrome, acute pancreatitis, and diabetic ketoacidosis. Clin. Chem. 31(7), 1109-1115 (1985).
70. Siddiqui RA, Harvey K, Stillwell W. Anticancer properties of oxidation products of docosahexaenoic acid. Chem. Phys. Lipids 153(1), 47-56 (2008).
71. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95(2), 351-358 (1979).
72. Chen X, Zhong Z, Xu Z, Chen L, Wang Y. 2′,7′-dichlorodihydrofluorescein as a fluorescent probe for reactive oxygen species measurement: forty years of application and controversy. Free Radic. Res. 44(6), 587-604 (2010).
73. 2-terminal kinase prevents the accumulation of reactive oxygen species and reduces necrotic damage in neural tumor cells that lack trophic support. Mol. Cancer Res. 5(1), 47-60 (2007).
74. Gardner AM, Xu FH, Fady C et al. Apoptotic vs. nonapoptotic cytotoxicity induced by hydrogen peroxide. Free Radic. Biol. Med. 22(1-2), 73-83 (1997).
75. Vanlangenakker N, Vanden Berghe T, Krysko DV, Festjens N, Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr. Mol. Med. 8(3), 207-220 (2008).
76. de Villiers WJ, Song Z, Nasser MS, Deaciuc IV, McClain CJ. 4-Hydroxynonenal-induced apoptosis in rat hepatic stellate cells: mechanistic approach. J. Gastroenterol. Hepatol. 22(3), 414-422 (2007).
77. Toit-Kohn JL, Louw L, Engelbrecht AM. Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways. J. Nutr. Biochem. 20(2), 106-114 (2009).
78. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51(3), 794-798 (1991).
79. Shen BW, Scanu AM, Kezdy FJ. Structure of human serum lipoproteins inferred from compositional analysis. Proc. Natl Acad. Sci. USA 74(3), 837-841 (1977).
80. Quilliot D, Walters E, Bohme P et al. Fatty acid abnormalities in chronic pancreatitis: effect of concomitant diabetes mellitus. Eur. J. Clin. Nutr. 57(3), 496-503 (2003).